Investigational drug · Phase 2
SAR447537
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alpha 1-Antitrypsin Deficiency, Emphysema.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "SAR447537"
First trial start
2023
Oct 12, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAR447537", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alpha 1-Antitrypsin Deficiency
- Emphysema
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "SAR447537" as an intervention, largest first.
- Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency EmphysemaActive, not recruiting
SanofiSanofi (SNY)
NCT05897424 · 185 participants (planned) · Start Jun 20, 2024 · Primary completion Jun 30, 2028
Drug: SAR447537 · For: Alpha 1-Antitrypsin Deficiency; Emphysema
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 40 sites in all
- Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD EmphysemaCompleted
SanofiSanofi (SNY)
NCT05856331 · 99 participants · Start Oct 12, 2023 · Primary completion Aug 6, 2025
Drug: SAR447537; Zemaira · For: Alpha 1-Antitrypsin Deficiency; Emphysema
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 65 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Alpha 1-Antitrypsin Deficiency
- BEAM-302Phase 21 trial
Beam Therapeutics Inc. · Alpha 1-Antitrypsin Deficiency
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.